• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations].

作者信息

Hoefsloot S, Urbanski G, Lacout C, Bouvard B, Lavigne C

机构信息

Service de rhumatologie, CHU Angers, 4, rue Larrey, Angers, France.

Service de médecine interne-immunologie clinique, CHU Angers, 4, rue Larrey, Angers, France.

出版信息

Rev Med Interne. 2021 Sep;42(9):616-624. doi: 10.1016/j.revmed.2021.03.326. Epub 2021 Jun 18.

DOI:10.1016/j.revmed.2021.03.326
PMID:34148673
Abstract

It is common to initiate a long-term corticosteroid therapy for inflammatory diseases. Various specialists are involved in this prescription, and associated measures to prevent side effects are not consensual, with the exception of osteoporosis. The specialty of the prescriber has indeed a significant impact on the attention paid to the adjuvant associated measures. The aim of this review was to draw a summary of the side effects of long-term corticosteroid therapy and of the existing recommendations related to associated measures to prevent them. Unfortunately, it is difficult to give clear recommendations because of the lack of evidence in some fields, especially as they should be adapted to patient's age and comorbidities. We propose a summary table of associated measures to long-term steroid therapy prescription and suggest a monitoring frequency.

摘要

相似文献

1
[Which adjuvant measures should be associated with long-term oral corticosteroid therapy in inflammatory diseases? A summary of existing French recommendations].
Rev Med Interne. 2021 Sep;42(9):616-624. doi: 10.1016/j.revmed.2021.03.326. Epub 2021 Jun 18.
2
[Long-term systemic corticosteroid-therapy associated measures: description of the French internal medicine physicians' practices].[长期全身性皮质类固醇治疗相关措施:法国内科医生的实践描述]
Rev Med Interne. 2008 Dec;29(12):975-80. doi: 10.1016/j.revmed.2008.04.001. Epub 2008 May 23.
3
Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.不同专业医生对糖皮质激素性骨质疏松症的判断差异。
J Rheumatol. 1998 Nov;25(11):2195-202.
4
Is enough attention being given to the adverse effects of corticosteroid therapy?对于皮质类固醇疗法的副作用是否给予了足够的关注?
J Clin Pharm Ther. 2000 Jun;25(3):227-34. doi: 10.1046/j.1365-2710.2000.00284.x.
5
[Association between prescription of long-term systemic glucocorticoid therapy associated measures and prescriber's medical speciality].[长期全身性糖皮质激素治疗相关措施的处方与开处方者医学专业之间的关联]
Rev Med Interne. 2019 Jul;40(7):427-432. doi: 10.1016/j.revmed.2018.10.388. Epub 2019 Jan 22.
6
[Description of French general practitioners' practices regarding long term systemic corticosteroid therapy-associated measures].
Rev Prat. 2009 Oct 20;59(8 Suppl):19-24.
7
Corticosteroid-induced osteoporosis.糖皮质激素性骨质疏松症
Am J Hosp Pharm. 1994 Jan 15;51(2):188-97; quiz 229-30.
8
[Corticosteroid-induced osteoporosis].[皮质类固醇性骨质疏松症]
Presse Med. 2004 Oct 9;33(17):1213-7. doi: 10.1016/s0755-4982(04)98891-4.
9
Management of corticosteroid-induced osteoporosis.
Drug Ther Bull. 2010 Sep;48(9):98-101. doi: 10.1136/dtb.2010.09.0047.
10
Corticosteroid osteoporosis: practical implications of recent trials.皮质类固醇性骨质疏松症:近期试验的实际意义
J Bone Miner Res. 2000 Sep;15(9):1645-9. doi: 10.1359/jbmr.2000.15.9.1645.